¸¸¼º ÄáÆϺ´ ȯÀÚ¿¡¼ °ñ´Ù°øÁõ
Osteoporosis in Patients with Chronic Kidney Disease
±Ç¿µÁÖ,
¼Ò¼Ó »ó¼¼Á¤º¸
±Ç¿µÁÖ ( Kwon Young-Joo )
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ½ÅÀå³»°ú
Abstract
Osteoporosis in chronic kidney disease (CKD) is also referred to as ¡®CKD with low bone mineral density (BMD)¡¯, because the cause of low BMD in CKD includes chronic kidney disease-mineral bone disorders (CKD-MBD) such as secondary hyperparathyroidism, osteomalacia, and adynamic bone disease. Diagnostic methods of osteoporosis in CKD include FRAX¢ç, BMD, and bone turnover markers as well as CKD-MBD biochemical parameters- calcium, P, alkaline phosphatase, PTH, and 25(OH)D3. The management of osteoporosis in CKD prioritizes CKD-MBD management over selection of bone anti-resorptive agents or osteo-anabolic agents according to clinical and laboratory findings.
Å°¿öµå
Chronic kidney failure; Chronic kidney insufficiency; Osteoporosis; Chronic kidney disease mineral bone disorder
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸